Clinical and Molecular Hepatology · 2022 · 10 citations · 17 references
Life SciencesBiochemistryPharmacologyDrug DiscoveryMolecular PharmacologyTranscriptomicsBiomarker DevelopmentBiomarkers Of Liver InjuryHepatic PathophysiologyLipid MetabolismLiver DiseaseLiver Function TestsBasket Trial DesignDipeptidyl PeptidasesDisease Biomarker DiscoveryDisease-specific BiomarkersInsulin-like Growth Factor-1Transcriptome AnalysisValidation Study DesignWhole Transcriptome Analysis
BACKGROUND/AIMS: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). METHODS: An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy. RESULTS: DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels. CONCLUSION: The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.
17
Kohjiro Ueki, Tatsuya Kondo, Yu‐Hua Tseng et al. · Proceedings of the National Academy of Sciences · 2004 · 382 citations · Full text
Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
Jeffrey Cui, Len Philo, Phirum Nguyen et al. · Journal of Hepatology · 2016 · 321 citations · Full text